What Is the Required Certainty of Evidence for the Implementation of Novel Techniques for the Treatment of Benign Prostatic Obstruction?
Datum
2019Language
en
Schlagwort
Zusammenfassung
Context: A large number of minimally invasive techniques have been developed for the surgical management of male lower urinary tract symptoms (LUTS) presumed to be secondary to benign prostatic obstruction (BPO) over the last 3 decades. Many have not stood the test of time often because they were overpromoted before there were sufficient data. Objective: The scope of this paper is to consider whether new devices, for the treatment of male LUTS/BPO, have been implemented prematurely in the past. We also examine the relative certainty of evidence (CoE) that is currently available for newer developing technologies and make recommendations about the CoE that should be demanded in the future before widespread implementation. Key messages: This evidence must provide adequate length of follow-up to allow proper information to be provided for patients before treatment choices are made and to be able to create recommendations in high-quality guidelines such as those of the European Association of Urology. It is not just within the domain of LUTS treatments that this is important, other urological devices, such as mesh devices, have been equally “guilty” and likewise devices in most other (surgical) specialities. We believe that there is a need for a set of requirements built around primary randomised controlled trials (RCTs) looking at both efficacy and safety, and secondary studies to confirm the reproducibility and generalisability of the first pivotal studies. Otherwise, there is a danger that a single pivotal study can be overexploited by device manufacturers. Studies that are needed include (1) proof of concept, (2) RCTs on efficacy and safety, as well as (3) cohort studies with a broad range of inclusion and exclusion criteria to confirm both reproducibility and generalisability of the benefits and harms. It is not the purpose of this paper to make judgements about individual treatments but simply to look at different treatments to provide verification for this debate. Patient summary: Many new treatment devices have been developed over the last 20–30 yr, often with inadequate medium- to long-term results. Many have not stood the test of time, but were heavily promoted by manufacturers, the press, and some doctors when they were first released, meaning that many patients had unsatisfactory results. This paper proposes minimum standards for the investigation of new treatments before their widespread promotion to patients. © 2019 European Association of UrologyIn the past, many minimally invasive techniques have been introduced and promoted ahead of their research evidence base. This paper makes recommendations for the certainty of evidence required in the future before widespread adoption of novel techniques for the management of lower urinary tract symptoms due to benign prostatic obstruction. © 2019 European Association of Urology
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Prostate cancer: ESMO consensus conference guidelines 2012
Horwich, A.; Hugosson, J.; de reijke, T.; Wiegel, T.; Fizazi, K.; Kataja, V.; Parker, C.; Bellmunt, J.; Berthold, D.; Bill-axelson, A.; Carlsson, S.; Daugaard, G.; De meerleer, G.; De reijke, T.; Dearnaley, D.; Fonteyne, V.; Gillessen, S.; Heinrich, D.; Kwiatkowski, M.; Nilsson, S.; Padhani, A.; Papandreou, C.; Roobol, M.; Sella, A.; Valdagni, R.; Van der kwast, T.; Verhagen, P. (2013)The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological ... -
Dietary factors and supplements influencing prostate specific-antigen (PSA) concentrations in men with prostate cancer and increased cancer risk: An evidence analysis review based on randomized controlled trials
Grammatikopoulou M.G., Gkiouras K., Papageorgiou S.Τ., Myrogiannis I., Mykoniatis I., Papamitsou T., Bogdanos D.P., Goulis D.G. (2020)The quest for dietary patterns and supplements efficient in down-regulating prostate-specific antigen (PSA) concentrations among men with prostate cancer (PCa) or increased PCa risk has been long. Several antioxidants, ... -
Prostate Volume as a Risk Factor for Lower Urinary Tract Symptoms: The Quest Continues
Gravas S. (2016)[No abstract available]